Notes from the Field: Delays in Identification and Treatment of a Case of Septicemic Plague — Navajo County, Arizona, 2020
Weekly / August 6, 2021 / 70(31);1063–1064
Ariella P. Dale, PhD1,2,3; Melissa Kretschmer, MA3; Irene Ruberto, PhD2; David M. Wagner, PhD4; Cathy Solomon5; Kenneth Komatsu, MPH2; Heather Venkat, DVM2,6 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
On June 18, 2020, a White non-Hispanic man aged 67 years sought care at an emergency department (ED) in Navajo County, Arizona, complaining of dehydration, nausea, weakness, and a chronic cough of 1.5 years’ duration. He had arrived in Navajo County from Nebraska approximately 9 days earlier. On physical exam, he was tachycardic and tachypneic. His chest radiograph and computed tomographic angiography chest scan with contrast were normal, and he was discharged after receiving intravenous fluids. He returned to the ED the next day (June 19) for treatment of three red and painful suspected insect bites on his leg and was discharged the same day with a diagnosis of cellulitis and two antibiotic prescriptions (Figure). He returned to the ED the following day (June 20) complaining of fever, dizziness, productive worsening cough, “swollen glands” (location not noted), weakness, and chills. He was hospitalized and received treatment with four antibiotics for a presumptive diagnosis of sepsis. Test results of nasopharyngeal specimens collected on June 18 and June 21 were negative for SARS-CoV-2, the virus that causes COVID-19, and other respiratory pathogens. On June 24, the hospital laboratory reported an atypical gram-negative isolate from a blood specimen, which was sent that day to a commercial reference laboratory for further identification using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF). The organism was identified as Yersinia pseudotuberculosis, a gram-negative, rod-shaped organism, and reported to the hospital on June 30. The patient was discharged from the hospital on July 1 with a peripherally inserted central catheter line and 3 additional days of a 14-day course of intravenous vancomycin.
On July 10, the hospital laboratory sent a blood culture isolate to Arizona State Public Health Laboratory (ASPHL) and Yersinia pestis was presumptively identified on July 12 using reverse transcriptase polymerase chain reaction testing. The hospital was notified of the presumptive results. After ASPHL culture confirmed Y. pestis on July 15 and classified the case as septicemic plague, the patient was prescribed a 10-day course of oral doxycycline and completed it. Delays in identification of the isolate as Y. pestis were attributed to initial misidentification of the pathogen and delays in laboratory reporting.
Blood samples collected on June 20 were cultured in the hospital. Arizona Administrative Code R9–6-204A requires laboratories to submit all Yersinia spp. isolates and report to ASPHL within 1 working day (1); in this case, a 10-day delay in submission of the isolate and report to ASPHL occurred. The reason for delay in testing or reporting by the reference laboratory or hospital laboratory is unclear.
Timely identification of a pathogen and treatment of the patient are critical to public health response and investigation of highly infectious pathogens such as Y. pestis. Plague is rare in Arizona and was last reported in 2017 in a Navajo County resident. The patient identified in 2020 had reported gloved handling of a dead pack rat before symptom onset; an environmental investigation noted many rodent habitats, but no fleas were collected. Typical transmission of Y. pestis to humans occurs through fleabites, exposure to sick animals (e.g., pets), or contact with contaminated tissues or body fluids (2). With rare pathogens, particularly in the context of the COVID-19 pandemic, timely laboratory identification is crucial for accurate clinical diagnosis and treatment; reeducation was conducted with the laboratories regarding the reporting requirements. This patient did not receive high-efficacy antibiotic treatment, a tetracycline, until approximately 30 days after symptom onset; he recovered, possibly in part because he received antibiotics with some demonstrated efficacy against Y. pestis, including trimethoprim/sulfamethoxazole, early in the illness course (3).
Misidentification of Y. pestis isolates as Y. pseudotuberculosis can occur with MALDI-TOF and other automated systems (4,5). Timely use of high-efficacy therapies including aminoglycosides and tetracyclines significantly increases the odds of survival in patients with plague (6). Rapid reporting might have led to timelier diagnosis of his acute illness and initiation of a more effective antibiotic therapy closer to disease onset.
Arizona State Public Health Laboratory; Jeff P. Lee, Wade Kartchner, Janelle Linn, Kathryn Mathewson, Randall Walton, Joshua Smith, Navajo County Department of Public Health Services, Arizona; Kris Bisgard, Kiersten Kugeler, Grace Marx, Amy Schwartz, CDC.
Corresponding author: Ariella P. Dale, firstname.lastname@example.org.
1Arizona Department of Health Services; 2Epidemic Intelligence Service, CDC; 3Maricopa County Department of Public Health, Phoenix, Arizona; 4Northern Arizona University, Flagstaff, Arizona; 5Navajo County Public Health Services District, Holbrook, Arizona; 6Career Epidemiology Field Officer Program, CDC.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Arizona Department of Health Services. Arizona laboratory reporting requirements. Phoenix, AZ: Arizona Department of Health Services; 2018. https://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/communicable-disease-reporting/lab-reporting-requirements.pdfpdf iconexternal icon
- Gage KL, Kosoy MY. Natural history of plague: perspectives from more than a century of research. Annu Rev Entomol 2005;50:505–28. https://doi.org/10.1146/annurev.ento.50.071803.130337external icon PMID:15471529external icon
- Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. MMWR Recomm Rep 2021;70(No. RR-3). https://doi.org/10.15585/mmwr.rr7003a1external icon PMID:34264565external icon
- American Society for Microbiology. Sentinel level clinical laboratory guidelines for suspected agents of bioterrorism and emerging infectious diseases: Yersinia pestis. Washington, DC: American Society for Microbiology; 2016. https://asm.org/ASM/media/Policy-and-Advocacy/LRN/Y-pestis-fixed-figures.pdfpdf iconexternal icon
- Tourdjman M, Ibraheem M, Brett M, et al. Misidentification of Yersinia pestis by automated systems, resulting in delayed diagnoses of human plague infections—Oregon and New Mexico, 2010–2011. Clin Infect Dis 2012;55:e58–60. https://doi.org/10.1093/cid/cis578external icon PMID:22715170external icon
- Kugeler KJ, Mead PS, Campbell SB, Nelson CA. Antimicrobial treatment patterns and illness outcome among United States patients with plague, 1942–2018. Clin Infect Dis 2020;70(Suppl 1):S20–6. https://doi.org/10.1093/cid/ciz1227external icon PMID:32435801external icon
FIGURE. Timeline of patient illness and laboratory identification of Yersinia pestis in a case of plague — Arizona, 2020
Abbreviations: ASPHL = Arizona State Public Health Laboratory; CT = computed tomography scan; CXR = chest radiograph; ED = emergency department; PCR = polymerase chain reaction; Pt. = patient; Rx = treatment; TMP/SMX = trimethoprim-sulfamethoxazole.
Suggested citation for this article: Dale AP, Kretschmer M, Ruberto I, et al. Notes from the Field: Delays in Identification and Treatment of a Case of Septicemic Plague — Navajo County, Arizona, 2020. MMWR Morb Mortal Wkly Rep 2021;70:1063–1064. DOI: http://dx.doi.org/10.15585/mmwr.mm7031a1external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.